Market Exclusive

IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Submission of Matters to a Vote of Security Holders

IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.Submission of Matters to a Vote of Security Holders.

At the Annual Meeting of Stockholders of IRIDEX Corporation
(IRIDEX or the Company) held on June 14, 2017 (the Annual
Meeting), the stockholders of IRIDEX re-elected the following
individuals to the Board of Directors. Each Director will serve
for the ensuing year or until their respective successors are
duly elected and qualified.

Nominee

Votes For

Votes Against

Abstentions

Broker Non Votes*

William M. Moore

5,690,433

405,413

1,000

2,884,491

Sanford Fitch

5,583,192

404,945

108,709

2,884,491

Ruediger Naumann-Etienne

5,769,711

214,426

112,709

2,884,491

George Marcellino

5,965,394

18,743

112,709

2,884,491

* Broker non-votes do not affect the outcome of the election.

In addition, the following proposals were voted on and approved
at the Annual Meeting.

Proposal

Votes For

Votes Against

Abstentions

Broker Non Votes

Proposal to ratify the appointment of BPM LLP as the
independent registered public accountants of the Company
for the fiscal year ending December 30, 2017

8,980,777

Proposal to approve, on a non-binding advisory basis, the
compensation of the Companys named executive officers as
described in the proxy statement

5,675,832

26,378

394,636

2,884,4914

Proposal to approve the amended and restated 2008 Equity
Incentive Plan

5,980,009

110,340

6,497

2,884,491

About IRIDEX CORPORATION (NASDAQ:IRIX)
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Exit mobile version